This study evaluates inclusion of National Comprehensive Cancer Network (NCCN) guideline recommended biomarkers for metastatic non–small cell lung cancer (NSCLC) in commercially available targeted next-generation sequencing (NGS) panels.
David L. Veenstra, PharmD, PhD
Advertisement
Articles by David L. Veenstra, PharmD, PhD
Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.
This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.
Advertisement
Latest Updated Articles
Do Targeted NGS Panels Include NSCLC Guideline-Recommended Biomarkers?February 12th 2026
Advertisement
Advertisement
Trending on AJMC
1
Patient Portal Messages Outpace Office Visits
2
Legend Biotech’s CAR T-cell Therapy Shows Early Promise in SCLC, Other Tumors
3
Flatiron’s AI-Driven Telescope Makes Data Access More User-Friendly
4
A Case for SGLT2 Inhibitors in Non-Diabetic CKD: Sandra Chaparro, MD
5